A Randomized Controlled Trial of Chinese Medicine on Nonmotor Symptoms in Parkinson’s Disease
Table 2
Efficacy result of JLT on Parkinson’s disease patient at week 32.
JLT
Placebo
Mean difference
95% confidence interval (CI)
p value
Movement Disorder Society-Sponsored Revision of Unified PD Rating Scale
(MDS-UPDRS)
Part I total score (nonmotor symptom)
−0.46 ± 6.61
0.84 ± 4.09
−1.30
−3.37 to 0.77
0.215
Q.1 Cognitive
−0.07 ± 0.97
0.00 ± 0.69
−0.07
−0.39 to 0.25
0.657
Q.2 Hallucinations
−0.04 ± 0.54
0.15 ± 0.52
−0.18
−0.38 to 0.02
0.075
Q.3 Depression
−0.07 ± 1.03
0.07 ± 0.72
−0.14
−0.48 to 0.19
0.393
Q.4 Anxious
−0.14 ± 0.82
−0.02 ± 0.71
−0.13
−0.41 to 0.16
0.393
Q.5 Apathy
−0.23 ± 1.36
−0.02 ± 0.87
−0.21
−0.64 to 0.22
0.327
Q.6 Dopamine dysregulation
−0.13 ± 0.63
−0.15 ± 0.52
0.02
−0.20 to 0.24
0.854
Q.7 Sleep
0.23 ± 1.03
0.13 ± 1.06
0.11
−0.29 to 0.50
0.597
Q.8 Daytime sleep
0.16 ± 0.91
0.11 ± 0.85
0.05
−0.28 to 0.38
0.759
Q.9 Pain
−0.02 ± 1.30
0.24 ± 1.05
−0.25
−0.70 to 0.19
0.261
Q.10 Urinary
−0.02 ± 0.73
0.02 ± 0.87
−0.04
−0.34 to 0.27
0.813
Q.11 Constipation
−0.13 ± 1.45
0.96 ± 4.35
−1.19
−2.30 to 0.13
0.079
Q12 Light headedness
0.04 ± 1.08
−0.04 ± 0.38
0.72
−0.23 to 0.38
0.641
Q13 Fatigue
−0.04 ± 1.21
−0.02 ± 0.97
−0.05
−0.47 to 0.36
0.796
Part II total score (motor symptom)
0.45 ± 4.13
1.05 ± 4.58
−0.61
−2.25 to 1.03
0.464
Part III total score (motor examination)
−0.52 ± 10.13
1.38 ± 8.27
−1.90
−5.38 to 1.58
0.282
Part IV total score (motor complications)
0.21 ± 3.56
0.65 ± 3.42
−0.44
−1.75 to 0.87
0.508
Nonmotor Symptom Assessment Scale for Parkinson’s Disease
(NMSS)
Total score
−2.27 ± 32.90
11.78 ± 28.93
−14.05
−25.71 to −2.39
0.019
D1 total cardiovascular
−0.89 ± 3.38
−0.15 ± 2.31
−0.75
−1.84 to 0.35
0.178
D2 total sleep/fatigue
3.63 ± 7.98
4.62 ± 7.08
−0.99
−3.83 to 1.84
0.490
D3 total mood/cognition
−3.54 ± 14.38
3.13 ± 9.36
−6.66
−11.23 to −2.10
0.005
D4 total perceptual/hallucinations
−0.88 ± 4.17
0.71 ± 3.04
−1.58
−2.96 to −0.21
0.024
D5 total attention/memory
−1.86 ± 6.07
−0.15 ± 7.08
−1.71
−4.20 to 0.77
0.174
D6 total gastrointestinal tract
−0.86 ± 5.15
0.98 ± 5.66
−1.84
−3.87 to 0.20
0.076
D7 total urinary
1.71 ± 7.57
1.47 ± 7.12
0.24
−2.52 to 3.01
0.863
D8 total sexual function
−0.71 ± 4.20
0.16 ± 3.81
−0.88
−2.39 to 0.63
0.251
D9 total miscellaneous
1.13 ± 6.41
1.00 ± 5.46
0.13
−2.11 to 2.36
0.912
p value wascomparing the score changes at week 32 between JLT group and placebo group by independent sample t-tests; values are given as mean ± S.D. Values in JLT group and placebo group are the score changed in the same group between week 32 and baseline (score at week 32 minus score at the baseline).
